Nasdaq scolds Oncology Venture after inadequate press release

Nasdaq Stockholm demands that Danish biotech company Oncology Venture provides the financial details of its acquisition of a promising cancer drug.

Photo: Oncology Venture, PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles